Prognosis prediction via histological evaluation of cellular heterogeneity in glioblastoma
Open Access
- 23 October 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Abstract
Glioblastomas (GBMs) are the most aggressive types of central nervous system tumors. Although certain genomic alterations have been identified as prognostic biomarkers of GBMs, the histomorphological features that predict their prognosis remain elusive. In this study, following an integrative diagnosis of 227 GBMs based on the 2021 World Health Organization classification system, the cases were histologically fractionated by cellular variations and abundance to evaluate the relationship between cellular heterogeneity and prognosis in combination with O-6-methylguanine-DNA methyltransferase gene promoter methylation (mMGMTp) status. GBMs comprised four major cell types: astrocytic, pleomorphic, gemistocytic, and rhabdoid cells. t-distributed stochastic neighbor embedding analysis using the histological abundance of heterogeneous cell types identified two distinct groups with significantly different prognoses. In individual cell component analysis, the abundance of gemistocytes showed a significantly favorable prognosis but confounding to mMGMTp status. Conversely, the abundance of epithelioid cells was correlated with the unfavorable prognosis. Linear model analysis showed the favorable prognostic utility of quantifying gemistocytic and epithelioid cells, independent of mMGMTp. The evaluation of GBM cell histomorphological heterogeneity is more effective for prognosis prediction in combination with mMGMTp analysis, indicating that histomorphological analysis is a practical and useful prognostication tool in an integrative diagnosis of GBMs.Keywords
This publication has 47 references indexed in Scilit:
- Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomasJournal of Neuro-Oncology, 2024
- Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomasJournal of Neuro-Oncology, 2023
- Clinicopathological characteristics and treatment outcomes of epithelioid glioblastomaNeurosurgical Review, 2021
- Giant cell glioblastoma is a distinctive subtype of glioma characterized by vulnerability to DNA damageBrain Tumor Pathology, 2019
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas2016
- Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastomaBrain Tumor Pathology, 2015
- Definition and Diagnostic Implications of Gemistocytic Astrocytomas: A Pathological PerspectiveJournal of Neuro-Oncology, 2005
- Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendrogliomaCancer, 2004
- Genetic evidence of the neoplastic nature of gemistocytes in astrocytomasActa Neuropathologica, 2001